Addendum: BMY stands to benefit more than most Big Pharma from a reduction in the US corporate tax rate.
On Twitter, people are trying to build a DCF model to calculate the NPV of what BMY will receive from MRK in the PD-1 patent settlement announced today, but they don't know what tax rate to apply to this income.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.